
## expected_masked gemma4-caa


### i001-appraise-agent-a1
```json
{
  "narrative": "The results of the exploratory analyses show that most of the tested binary and categorical predictors (H1-H9, H12) have negligible effects on log_pfs_months, with mean differences far below the 0.2 clinical significance threshold. However, feature_006 (H10) and feature_025 (H11) show very strong associations with log_pfs_months. In both cases, the estimates (~ -0.45) are large and statistically significant, but the effect is in the opposite direction of the initial hypothesis (exposed < comparator). Because the absolute difference (0.45) is more than double the clinical significance threshold (0.2), these findings are highly meaningful. I reject the positive claims but maintain active investigation to formally document the negative association. I am requesting independent validation for the effect of feature_006.",
  "assessments": [
    {
      "claim": "H1",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R1"
      ]
    },
    {
      "claim": "H2",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R2"
      ]
    },
    {
      "claim": "H3",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R3"
      ]
    },
    {
      "claim": "H4",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R4"
      ]
    },
    {
      "claim": "H5",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R5"
      ]
    },
    {
      "claim": "H6",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R6"
      ]
    },
    {
      "claim": "H7",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R7"
      ]
    },
    {
      "claim": "H8",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R8"
      ]
    },
    {
      "claim": "H9",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R9"
      ]
    },
    {
      "claim": "H10",
      "status": "reject",
      "investigation": "active",
      "evidence": [
        "R10"
      ]
    },
    {
      "claim": "H11",
      "status": "reject",
      "investigation": "active",
      "evidence": [
        "R11"
      ]
    },
    {
      "claim": "H12",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R12"
      ]
    }
  ],
  "validate": "H10"
}
```

### i002-appraise-agent-a1
```json
{
  "narrative": "The results confirm that feature_006 and feature_025 are both strong, independent negative predictors of progression-free survival (log_pfs_months). \n\nFirst, the effect of feature_006 remains strongly negative even within the feature_025=1 subgroup (H15: estimate 0.448, direction -1), and the interaction test (H19/H23) shows no significant difference in the effect of feature_006 based on feature_025 status. This indicates that these two biomarkers provide independent signals. \n\nSecond, I tested whether the effect of feature_006 is modified by the dependency scores (feature_002, feature_013, feature_042). None of the interaction tests (H20, H21, H22) were statistically significant, suggesting that the negative impact of feature_006 is consistent across different levels of dependency.\n\nThird, the exploration of continuous variables using split-points (H16, H17, H18) was unsuccessful. Feature_014 showed no clinically meaningful difference, and features 007 and 012 had insufficient observations in the comparison cells.\n\nI am now accepting the negative associations for feature_006 (H13), feature_025 (H14), and feature_006 within the feature_025=1 subgroup (H15). I am requesting independent validation for the effect of feature_025 to mirror the validation performed for feature_006.",
  "assessments": [
    {
      "claim": "H13",
      "status": "accept",
      "investigation": "closed",
      "evidence": [
        "R10",
        "R13"
      ]
    },
    {
      "claim": "H14",
      "status": "accept",
      "investigation": "closed",
      "evidence": [
        "R11"
      ]
    },
    {
      "claim": "H15",
      "status": "accept",
      "investigation": "closed",
      "evidence": [
        "R14"
      ]
    },
    {
      "claim": "H16",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R15"
      ]
    },
    {
      "claim": "H17",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R16"
      ]
    },
    {
      "claim": "H18",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R17"
      ]
    },
    {
      "claim": "H19",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R18"
      ]
    },
    {
      "claim": "H20",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R19"
      ]
    },
    {
      "claim": "H21",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R20"
      ]
    },
    {
      "claim": "H22",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R21"
      ]
    },
    {
      "claim": "H23",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R22"
      ]
    }
  ],
  "validate": "H14"
}
```

### i010-synthesize-agent-a1
```json
{
  "narrative": "I have completed the final synthesis of the investigation into predictors of progression-free survival (log_pfs_months). The research identified and validated four strong binary predictors: feature_006, feature_025, and feature_028 (all associated with shorter PFS) and feature_041 (associated with longer PFS), each with a clinically significant effect size of approximately 0.45 log-months. Additionally, feature_036 was identified as a moderate positive predictor (~0.16 log-months). Extensive interaction testing revealed that these effects act independently and are not meaningfully modified by other binary predictors or the measured continuous variables. All viable binary comparisons and interactions have been explored. The remaining unresolved claims concerning continuous variables (H38-H42, H76-H83) are not scientifically informative given the literal-value matching constraints of the framework and are therefore considered closed. No further investigations are warranted in this dataset.",
  "assessments": []
}
```

### i025-synthesize-agent-a1
```json
{
  "narrative": "The systematic investigation into the predictors of log_pfs_months is now complete. We have identified and validated five binary predictors with clinically significant effects: four strong drivers (feature_006, feature_025, and feature_028 as negative predictors; feature_041 as a positive predictor), all showing effect sizes of approximately 0.45 log-months, and one moderate positive predictor (feature_036) with an effect size of approximately 0.16 log-months. Extensive interaction screening between these predictors and other available variables, including continuous predictors and other binary flags, consistently yielded results well below the clinical significance threshold of 0.1 log-months, suggesting these drivers act independently. While framework constraints limited the direct assessment of main effects for continuous variables, they showed no meaningful roles as modifiers. The evidence documented in the ledger fully supports these conclusions."
}
```

## expected_masked gemma4-control


### i001-appraise-agent-a1
```json
{
  "assessments": [
    {
      "claim": "H1",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R1"
      ]
    },
    {
      "claim": "H2",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R2"
      ]
    },
    {
      "claim": "H3",
      "status": "reject",
      "investigation": "active",
      "evidence": [
        "R3"
      ]
    },
    {
      "claim": "H4",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R4"
      ]
    },
    {
      "claim": "H5",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R5"
      ]
    },
    {
      "claim": "H6",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R6"
      ]
    },
    {
      "claim": "H7",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R7"
      ]
    },
    {
      "claim": "H8",
      "status": "reject",
      "investigation": "active",
      "evidence": [
        "R8"
      ]
    },
    {
      "claim": "H9",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R9"
      ]
    },
    {
      "claim": "H10",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R10"
      ]
    },
    {
      "claim": "H11",
      "status": "accept",
      "investigation": "active",
      "evidence": [
        "R11"
      ]
    },
    {
      "claim": "H12",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R12"
      ]
    }
  ],
  "validate": "H11",
  "narrative": "The initial screen of 12 predictors revealed three strong signals. H11 (feature_003 level 2.0 vs 0.0) shows a statistically significant and clinically meaningful positive association with log_pfs_months (MD = 0.45, p < 0.05), which corresponds to a roughly 57% increase in PFS. I accept this claim and request independent validation. Conversely, H3 (feature_006) and H8 (feature_025) showed strong associations in the opposite direction of the original hypotheses (MD ≈ -0.45), which is clinically meaningful (roughly 36% decrease in PFS). I reject the original claims but keep these investigations active to propose refinements with the correct direction. The remaining predictors showed negligible effect sizes well below the 0.1 clinical significance threshold and are marked as closed."
}
```

### i002-appraise-agent-a1
```json
{
  "assessments": [
    {
      "claim": "H15",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R14"
      ]
    },
    {
      "claim": "H16",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R15"
      ]
    },
    {
      "claim": "H17",
      "status": "accept",
      "investigation": "active",
      "evidence": [
        "R16"
      ]
    },
    {
      "claim": "H18",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R17"
      ]
    },
    {
      "claim": "H19",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R18"
      ]
    },
    {
      "claim": "H20",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R19"
      ]
    },
    {
      "claim": "H21",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R20"
      ]
    },
    {
      "claim": "H22",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R21"
      ]
    },
    {
      "claim": "H23",
      "status": "reject",
      "investigation": "active",
      "evidence": [
        "R22"
      ]
    },
    {
      "claim": "H24",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R23"
      ]
    },
    {
      "claim": "H25",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R24"
      ]
    },
    {
      "claim": "H26",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R25"
      ]
    }
  ],
  "narrative": "The expanded screen of binary and categorical predictors yielded two notable results. H17 (feature_036) shows a statistically significant and clinically meaningful positive association with log_pfs_months (MD = 0.156, p < 0.05), which I accept and request for validation. H23 (feature_028) shows a strong association but in the opposite direction of the proposed hypothesis (MD ≈ -0.45); I reject the original claim but keep the investigation active to propose a refinement with the correct direction. Other results (H15, H16, H18-H22, H24-H26) were either negligible or below the 0.1 clinical significance threshold and are marked as closed. Interestingly, feature_028 (H23) shows a magnitude of effect similar to feature_006 and feature_025, suggesting a pattern among certain predictors.",
  "validate": "H17"
}
```

### i010-synthesize-agent-a1
```json
{
  "narrative": "I have assessed the validation evidence for H28. The independent validation result (R69) shows a mean difference of 0.4576 (signed to the negative direction), which is highly consistent with the discovery evidence (R22) and confirms a strong negative association between feature_028 (level 1.0) and log_pfs_months. \n\nAt this stage, the investigation has robustly characterized the primary predictors of log_pfs_months. We have validated strong positive predictors (feature_003 level 2.0, feature_041 level 1.0), strong negative predictors (feature_006 level 1.0, feature_025 level 1.0, feature_028 level 1.0), and a moderate positive predictor (feature_036 level 1.0). Furthermore, extensive interaction testing has demonstrated that these markers act additively. With all binary features screened and the primary signals independently validated, I conclude that the research goal has been achieved.",
  "assessments": [
    {
      "claim": "H28",
      "status": "accept",
      "investigation": "closed",
      "evidence": [
        "R69"
      ]
    }
  ]
}
```

### i025-synthesize-agent-a1
```json
{
  "narrative": "The systematic investigation into the predictors of progression-free survival (`log_pfs_months`) is now complete. All binary predictors were screened, and those with clinically significant effects were independently validated. Extensive interaction testing demonstrated that these predictors operate additively, as no meaningful interaction effects were discovered. The findings are summarized in the final report provided in the previous synthesis narrative. No further analyses or assessments are required."
}
```

## surprising_masked gemma4-caa


### i001-appraise-agent-a1
```json
{
  "narrative": "I have assessed the results of the initial screening (H1-H12). The baseline mean of log_pfs_months is approximately 2.51, meaning the clinical significance threshold (10%) is a mean difference of approximately 0.25. \n\nFeature_006 (H3) shows a highly significant and clinically meaningful positive association with log_pfs_months (estimate = 0.452, 95% CI [0.444, 0.461]), which represents an approximately 18% increase. I accept this claim.\n\nFeature_025 (H8) shows a highly significant and clinically meaningful negative association (estimate = -0.451, 95% CI [-0.460, -0.442] for a positive hypothesis). This indicates that feature_025 = 1 is associated with significantly shorter progression-free survival compared to feature_025 = 0. While the predictor is highly meaningful, the specific claim (exposed > comparator) is rejected. I will keep the investigation for feature_025 active to formally test the opposite direction.\n\nAll other predictors (H1, H2, H4-H7, H9-H12) showed negligible effects (estimates < 0.01) that are far below the clinical significance threshold and are largely non-significant. I reject these claims and close their investigation.",
  "assessments": [
    {
      "claim": "H1",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R1"
      ]
    },
    {
      "claim": "H2",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R2"
      ]
    },
    {
      "claim": "H3",
      "status": "accept",
      "investigation": "active",
      "evidence": [
        "R3"
      ]
    },
    {
      "claim": "H4",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R4"
      ]
    },
    {
      "claim": "H5",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R5"
      ]
    },
    {
      "claim": "H6",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R6"
      ]
    },
    {
      "claim": "H7",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R7"
      ]
    },
    {
      "claim": "H8",
      "status": "reject",
      "investigation": "active",
      "evidence": [
        "R8"
      ]
    },
    {
      "claim": "H9",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R9"
      ]
    },
    {
      "claim": "H10",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R10"
      ]
    },
    {
      "claim": "H11",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R11"
      ]
    },
    {
      "claim": "H12",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R12"
      ]
    }
  ],
  "validate": "H3"
}
```

### i002-appraise-agent-a1
```json
{
  "narrative": "I have appraised the results of the interaction tests and the continued screening of binary predictors. \n\nFeature_025 (H13) is confirmed to be associated with a clinically significant decrease in progression-free survival (estimate ≈ 0.45, approximately an 18% reduction compared to the baseline mean of 2.51). I accept this claim and request independent validation to solidify this finding.\n\nNone of the interaction tests showed significant results. The interaction between feature_006 and feature_025 (H14) was negligible, and the interactions between either of these strong predictors and the dependency scores (using median splits, H15-H20) were also non-significant. This suggests that the effects of feature_006 and feature_025 are independent and consistent across the tested dependency subgroups.\n\nIn the additional screening, feature_036 (H21) showed a statistically significant positive association with log_pfs_months (estimate ≈ 0.15). However, this represents approximately a 6% increase, which falls below the predefined clinical significance threshold of 10% (approx. 0.25). Therefore, I reject this claim as not clinically meaningful. The other screened features (H22-H24) showed no meaningful association.\n\nWith the primary binary predictors screened and their interactions with dependency scores tested, I have established a set of strong, independent predictors of progression-free survival in this dataset.",
  "assessments": [
    {
      "claim": "H13",
      "status": "accept",
      "investigation": "closed",
      "evidence": [
        "R8"
      ]
    },
    {
      "claim": "H14",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R14"
      ]
    },
    {
      "claim": "H15",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R15"
      ]
    },
    {
      "claim": "H16",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R16"
      ]
    },
    {
      "claim": "H17",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R17"
      ]
    },
    {
      "claim": "H18",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R18"
      ]
    },
    {
      "claim": "H19",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R19"
      ]
    },
    {
      "claim": "H20",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R20"
      ]
    },
    {
      "claim": "H21",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R21"
      ]
    },
    {
      "claim": "H22",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R22"
      ]
    },
    {
      "claim": "H23",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R23"
      ]
    },
    {
      "claim": "H24",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R24"
      ]
    }
  ],
  "validate": "H13"
}
```

### i010-synthesize-agent-a1
```json
{
  "assessments": [
    {
      "claim": "H21",
      "status": "accept",
      "investigation": "closed",
      "evidence": [
        "R21",
        "R91"
      ]
    }
  ],
  "narrative": "The independent validation result for H21 confirms that `feature_036` is a robust predictor of `log_pfs_months`. The validation estimate of 0.158 [0.145, 0.171] is highly consistent with the discovery estimate of 0.151 [0.142, 0.160]. This effect size (~16% increase in PFS) is clinically significant, exceeding the 10% threshold. With this confirmation, the previously listed 'unresolved uncertainty' regarding `feature_036` is now a supported finding. This completes the validation of all identified meaningful predictors. I am now updating the final scientific report to include `feature_036` as a secondary, validated predictor.\n\n### Final Scientific Report\n\n**Supported Findings**\nI have identified five robust and additive predictors of `log_pfs_months`, all of which were independently validated:\n\n1. **Primary Predictors**: Four predictors each with an effect size of approximately 0.44 to 0.46 log units, representing a clinically significant difference of approximately 45-50% in progression-free survival:\n    - **Positive**: `feature_006` and `feature_041` (the latter is perfectly collinear with `feature_003` level 2).\n    - **Negative**: `feature_025` and `feature_028`.\n\n2. **Secondary Predictor**: `feature_036` exhibits a moderate positive effect of approximately 0.15 to 0.16 log units, representing a clinically significant increase of approximately 16% in progression-free survival.\n\n**Negative Findings**\n- **Interactions**: Extensive testing for interaction effects between these predictors and various subgroups—including binary predictors and splits at the 25th, 50th, and 75th percentiles of all continuous variables—yielded no clinically meaningful results. The effects of these predictors appear to be additive and stable across the tested populations.\n- **Other Predictors**: A comprehensive screen of other binary and categorical variables (including `feature_001`, `feature_005`, `feature_008`, `feature_010`, `feature_017`, `feature_020`, `feature_022`, `feature_024`, `feature_030`, `feature_033`, `feature_034`, `feature_039`, `feature_040`, and `feature_043`) revealed no associations that met the clinical significance threshold.\n\n**Conclusion**\nThe most informative result of this study is the identification of a five-factor additive model (`feature_006`, `feature_041`, `feature_025`, `feature_028`, and `feature_036`) that explains significant variance in `log_pfs_months`. The remarkable consistency between discovery and validation datasets suggests these are stable markers of outcome within this dataset.",
  "research_notes": "Final Predictor Model: Five independent, robust, and additive predictors of log_pfs_months were identified and validated.\n- Primary Positive predictors: feature_006 and feature_041 (perfectly collinear with feature_003 level 2). Effect size ~0.45 log units.\n- Primary Negative predictors: feature_025 and feature_028. Effect size ~0.45 log units.\n- Secondary Positive predictor: feature_036. Effect size ~0.15 log units.\n\nAll five effects were confirmed via independent validation. Extensive interaction analyses across binary and continuous (quartile and median splits) subgroups demonstrated that these effects are stable and act additively. No other predictors reached the clinical significance threshold."
}
```

### i025-synthesize-agent-a1
```json
{
  "narrative": "The research goal has been fully satisfied. Through a systematic process of discovery and independent validation, we have identified six clinically significant predictors of `log_pfs_months`. Five of these exhibit strong effects (~0.45 log units), while one shows a moderate effect (~0.15 log units). An exhaustive search for interaction effects across a wide array of subgroups and features found no modifiers that met the clinical significance threshold (0.10 log units), confirming that these predictors act in a stable, approximately additive manner within this dataset. No further analyses are scientifically warranted."
}
```

## surprising_masked gemma4-control


### i001-appraise-agent-a1
```json
{
  "narrative": "The initial screen of 12 predictors reveals three strong associations with progression-free survival (log_pfs_months), all of which far exceed the clinical significance threshold of 0.1. \n\nFirst, feature_006 (H3) and feature_003=2 (H7) are strongly associated with improved PFS, with mean differences of 0.452 and 0.446 respectively, and very tight confidence intervals. \n\nSecond, feature_025 (H5) shows a strong effect in the opposite direction of the hypothesis; the estimate of -0.451 indicates that feature_025=1 is associated with significantly worse PFS than feature_025=0. Consequently, the claim H5 (exposed > comparator) is rejected.\n\nMost other predictors (H1, H2, H4, H6, H8, H9, H10, H11, H12) show no meaningful association, with estimates near zero and confidence intervals spanning zero. I will close the investigation into these null predictors and keep the investigation active for the strong predictors to explore potential interactions or refinements in future iterations.",
  "assessments": [
    {
      "claim": "H1",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R1"
      ]
    },
    {
      "claim": "H2",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R2"
      ]
    },
    {
      "claim": "H3",
      "status": "accept",
      "investigation": "active",
      "evidence": [
        "R3"
      ]
    },
    {
      "claim": "H4",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R4"
      ]
    },
    {
      "claim": "H5",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R5"
      ]
    },
    {
      "claim": "H6",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R6"
      ]
    },
    {
      "claim": "H7",
      "status": "accept",
      "investigation": "active",
      "evidence": [
        "R7"
      ]
    },
    {
      "claim": "H8",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R8"
      ]
    },
    {
      "claim": "H9",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R9"
      ]
    },
    {
      "claim": "H10",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R10"
      ]
    },
    {
      "claim": "H11",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R11"
      ]
    },
    {
      "claim": "H12",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R12"
      ]
    }
  ],
  "validate": "H3"
}
```

### i002-appraise-agent-a1
```json
{
  "narrative": "The second round of binary predictor screening and interaction testing provides several key insights. \n\nFirst, I discovered two more predictors with strong, clinically significant effects of approximately 0.45 log units: feature_041=1 is strongly associated with improved PFS (H23: 0.447 [0.435, 0.459]), while feature_028=1 is strongly associated with worse PFS (H24: -0.455 [-0.466, -0.443]). This brings the total of high-magnitude predictors to five (three positive, two negative), all showing remarkably similar effect sizes.\n\nSecond, all three tested interactions (H13, H14, H15) were null, with estimates very close to zero. This suggests that the effects of feature_006, feature_003, and feature_025 are additive and do not significantly modify each other's impact on PFS.\n\nThird, feature_024=1 showed a statistically significant positive effect (H18: 0.093 [0.065, 0.121]). While this is just below the 0.1 clinical significance threshold, it is distinct from the ~0.45 magnitude of the other markers and warrants further monitoring, though it is currently marked as unresolved.\n\nAll other binary predictors (feature_039, feature_030, feature_043, feature_034, feature_033, feature_020) showed no meaningful association.\n\nI will now request independent validation for the newly discovered positive predictor, feature_041.",
  "assessments": [
    {
      "claim": "H13",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R14"
      ]
    },
    {
      "claim": "H14",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R15"
      ]
    },
    {
      "claim": "H15",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R16"
      ]
    },
    {
      "claim": "H16",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R17"
      ]
    },
    {
      "claim": "H17",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R18"
      ]
    },
    {
      "claim": "H18",
      "status": "unresolved",
      "investigation": "active",
      "evidence": [
        "R19"
      ]
    },
    {
      "claim": "H19",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R20"
      ]
    },
    {
      "claim": "H20",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R21"
      ]
    },
    {
      "claim": "H21",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R22"
      ]
    },
    {
      "claim": "H22",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R23"
      ]
    },
    {
      "claim": "H23",
      "status": "accept",
      "investigation": "active",
      "evidence": [
        "R24"
      ]
    },
    {
      "claim": "H24",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R25"
      ]
    }
  ],
  "validate": "H23"
}
```

### i010-synthesize-agent-a1
```json
{
  "narrative": "### Final Scientific Report: Predictors of Progression-Free Survival (log_pfs_months)\n\n**Objective:**\nTo identify predictors and subgroups associated with clinically meaningful differences in progression-free survival (PFS), measured as `log_pfs_months`. Clinical significance was defined as a relative difference in outcome of 10% or greater, which corresponds to an absolute difference of approximately $\\ge |0.25|$ log units given the sample mean of 2.51.\n\n**Supported Findings:**\nThe investigation identified five high-magnitude categorical predictors that meet the threshold for clinical significance. Each of these predictors exhibits an absolute effect size of approximately 0.44 to 0.45 log units, indicating they are the primary drivers of PFS in this dataset.\n\n1. **Strong Positive Predictors:**\n   - `feature_006=1` (R3, R13): Associated with an increase of $\\sim 0.45$ log units. Independently validated.\n   - `feature_003=2` (R7, R42): Associated with an increase of $\\sim 0.44$ log units. Independently validated.\n   - `feature_041=1` (R24, R26): Associated with an increase of $\\sim 0.44$ log units. Independently validated.\n\n2. **Strong Negative Predictors:**\n   - `feature_025=1` (R5): Associated with a decrease of $\\sim 0.45$ log units.\n   - `feature_028=1` (R25): Associated with a decrease of $\\sim 0.45$ log units.\n\n**Negative and Moderate Findings:**\n- **Moderate Predictors:** Several predictors showed statistically significant associations but failed to reach the clinical significance threshold of 0.25 log units. These include `feature_036=1` ($\\sim 0.15$ log units; R28, R35), `feature_024=1` ($\\sim 0.09$ log units; R19), and `feature_027` (R53).\n- **Additivity and Interaction:** Extensive testing for interactions among the strong drivers (H13, H14, H15, H27-H31), between strong and moderate predictors (H32, H40, H41, H45, H46, H51-H58), and between strong drivers and continuous variables at the 75th percentile (H59-H69) consistently yielded non-significant results or effect sizes negligible compared to the main effects. This strongly supports an additive model where these predictors operate independently.\n- **Non-Linearity:** The effect of `feature_003` is specific to level 2; comparison of level 1 vs level 0 (R41) showed no meaningful difference, suggesting the association is not a simple linear dose-response.\n\n**Unresolved Uncertainty and Limitations:**\n- **Continuous Variables:** Truly continuous predictors (e.g., age `feature_014` and dependency scores `feature_002`, `feature_013`, `feature_042`) could not be tested for main effects due to tool constraints requiring exact matches. However, interaction tests suggest that the effects of the strong drivers are robust across different strata of these variables.\n- **Generalizability:** These findings are specific to the supplied dataset; conclusions regarding causality or generalizability to broader clinical populations remain uncertain.\n\n**Conclusion:**\nProgression-free survival in this population is primarily determined by five additive categorical predictors, with three strong positive drivers and two strong negative drivers, each contributing approximately 0.45 log units to the outcome. The model is robust across the tested range of continuous variables.",
  "assessments": [
    {
      "claim": "H18",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R19"
      ]
    }
  ]
}
```

### i025-synthesize-agent-a1
```json
{
  "narrative": "The investigation into the predictors of log_pfs_months is now complete. We have systematically mapped the categorical predictor space and sampled continuous variables, identifying a set of primary drivers that exhibit clinically meaningful effects (defined as a relative difference of 10% or greater, corresponding to approximately 0.095 log units). The evidence supports an additive model where progression-free survival is driven by five key features.\n\n### Supported Findings\n\n**Strong Positive Drivers (~ +0.45 log units):**\n- **feature_006**: Associated with a significant increase in log_pfs_months (Discovery: +0.452 [0.444, 0.461]; Validation: +0.446 [0.434, 0.459]).\n- **feature_003 = 2.0 / feature_041 = 1.0**: These two predictors are highly collinear and both show a similar strong positive effect (feature_003=2.0 Discovery: +0.447 [0.433, 0.460], Validation: +0.441 [0.421, 0.461]; feature_041=1.0 Discovery: +0.447 [0.435, 0.459], Validation: +0.436 [0.418, 0.454]).\n\n**Strong Negative Drivers (~ -0.45 log units):**\n- **feature_025 = 1.0**: Associated with a strong decrease in log_pfs_months (Discovery: -0.451 [-0.460, -0.442]).\n- **feature_028 = 1.0**: Associated with a strong decrease in log_pfs_months (Discovery: -0.455 [-0.466, -0.443]).\n\n**Moderate Positive Driver (~ +0.15 log units):**\n- **feature_036 = 1.0**: Associated with a moderate increase in log_pfs_months (Discovery: +0.151 [0.142, 0.160]; Validation: +0.158 [0.145, 0.171]).\n\n**Additivity:**\nMultiple interaction tests between these primary drivers and other features (e.g., H13, H14, H27, H29) were negative or clinically negligible, supporting the conclusion that these effects are primarily additive.\n\n### Negative Findings\n\n- **Non-Predictive Categorical Features**: Numerous features (including feature_001, 005, 008, 040, 004, 010, 017, 039, 030, 043, 034, 033, 020, and 022) showed no clinically meaningful association with the outcome.\n- **Low-Impact Features**: feature_024 was investigated and validated to have an effect below the 10% clinical significance threshold (Validation: +0.063 [0.021, 0.105]).\n- **Continuous Variables**: Sampling of continuous variables (e.g., feature_014, 011, 018, 038, 009, 027, 035) failed to identify any linear or threshold-based effects that reached clinical significance.\n\n### Unresolved Uncertainty\n\n- **Biological Interpretation**: Due to the use of opaque labels, the biological identity and mechanism of these features remain unknown.\n- **Non-Linear Continuous Effects**: While sampling of continuous variables was negative, the possibility of complex non-linear relationships remains, as the predictor space was not exhaustively searched.\n- **Generalizability**: These findings are specific to the supplied dataset and cannot be generalized to other populations without further external validation.\n\n### Conclusion\n\nThe research goal has been satisfied. The progression-free survival in this dataset is primarily determined by an additive combination of the five identified categorical features, with four exhibiting strong effects and one exhibiting a moderate effect."
}
```

## surprising_unmasked gemma4-caa


### i001-appraise-agent-a1
```json
{
  "assessments": [
    {
      "claim": "H1",
      "status": "reject",
      "investigation": "active",
      "evidence": [
        "R1"
      ]
    },
    {
      "claim": "H2",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R2"
      ]
    },
    {
      "claim": "H3",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R3"
      ]
    },
    {
      "claim": "H4",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R4"
      ]
    },
    {
      "claim": "H5",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R5"
      ]
    },
    {
      "claim": "H6",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R6"
      ]
    },
    {
      "claim": "H7",
      "status": "reject",
      "investigation": "active",
      "evidence": [
        "R7"
      ]
    },
    {
      "claim": "H8",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R8"
      ]
    },
    {
      "claim": "H9",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R9"
      ]
    },
    {
      "claim": "H10",
      "status": "accept",
      "investigation": "active",
      "evidence": [
        "R10"
      ]
    },
    {
      "claim": "H11",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R11"
      ]
    },
    {
      "claim": "H12",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R12"
      ]
    }
  ],
  "narrative": "I have appraised the discovery results for the initial baseline screen. \n\n1. Research Marker D (H10) is accepted. The mean difference is 0.151 (95% CI [0.142, 0.160]), which exceeds the clinical significance threshold of approximately 0.1 log-units (10% relative difference). This suggests Marker D is a positive predictor of progression-free survival in this dataset.\n\n2. A surprising finding appears for ECOG PS >= 2 (H1) and NLR >= 3 (H7). While these were hypothesized as poor prognostic factors (Direction -1), the evidence shows a strong *increase* in log_pfs_months (Raw MD ≈ +0.45 for both), which is the opposite of clinical expectation. These claims are rejected, but I am keeping the investigations active to explore this counter-intuitive reversal.\n\n3. All other baseline markers—including TMB high, KRAS G12C, STK11 mutation, and low albumin—showed effects that were either negligible or statistically non-significant. Similarly, the targeted treatment interactions for Osimertinib and Sotorasib did not show clinically meaningful effects. Research markers E and F also failed to show association. These investigations are closed.",
  "validate": "H10"
}
```

### i002-appraise-agent-a2
```json
{
  "assessments": [
    {
      "claim": "H13",
      "status": "accept",
      "investigation": "active",
      "evidence": [
        "R1"
      ]
    },
    {
      "claim": "H14",
      "status": "accept",
      "investigation": "active",
      "evidence": [
        "R7"
      ]
    },
    {
      "claim": "H15",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R14"
      ]
    },
    {
      "claim": "H16",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R15"
      ]
    },
    {
      "claim": "H17",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R16"
      ]
    },
    {
      "claim": "H18",
      "status": "reject",
      "investigation": "active",
      "evidence": [
        "R17"
      ]
    },
    {
      "claim": "H19",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R18"
      ]
    },
    {
      "claim": "H20",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R19"
      ]
    },
    {
      "claim": "H21",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R20"
      ]
    },
    {
      "claim": "H22",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R21"
      ]
    },
    {
      "claim": "H23",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R22"
      ]
    },
    {
      "claim": "H24",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R23"
      ]
    }
  ],
  "proposals": [
    {
      "outcome": "log_pfs_months",
      "exposure": "crp_mg_l_ge_10",
      "exposed": 1.0,
      "comparator": 0.0,
      "contrast": "mean_difference",
      "direction": -1,
      "anticipated_direction": -1,
      "initial_status": "unresolved",
      "parent": "H18",
      "motivating_evidence": [
        "R17"
      ]
    }
  ],
  "narrative": "The analyses have clarified the 'inflammation paradox' in this dataset. ECOG PS >= 2 and NLR >= 3 are very strong positive predictors of PFS (Raw MD ≈ +0.45), and this effect is remarkably consistent across treatment arms, as seen in the Olaparib (H21, H23) and Osimertinib (H22, H24) groups. This suggests the reversal is a general property of the dataset rather than a treatment-specific interaction. Interestingly, CRP >= 10 (H18) does not follow this pattern; it is a strong negative predictor (Raw MD ≈ -0.45), which aligns with clinical expectations. I am accepting the counter-intuitive positive effects of ECOG PS and NLR for this dataset but requesting validation for ECOG PS (H13) given the magnitude of the reversal. Pembrolizumab showed no clinically meaningful interaction with these markers or Marker D. The analysis for PD-L1 (H17) failed due to insufficient cell size at the chosen threshold.",
  "validate": "H13"
}
```

### i010-synthesize-agent-a1
```json
{
  "narrative": "I have completed the investigation into predictors of progression-free survival (log_pfs_months). The analysis successfully identified and validated several key prognostic markers and revealed a highly unconventional trend regarding clinical burden markers. Stage IV disease and high CRP (>= 10 mg/L) are strongly associated with decreased PFS. Conversely, Research Marker D and BRCA2 mutations are associated with a moderate increase in PFS. \n\nMost notably, the dataset exhibits an 'anti-clinical' pattern: ECOG PS >= 2 and NLR >= 3 are consistently and strongly associated with increased PFS, regardless of disease stage or CRP levels. This paradox was initially mistaken for a distribution effect but was confirmed as a consistent positive association across subgroups (H66, H67, H70, H71). Extensive testing of treatment effects and marker-treatment interactions yielded no scientifically meaningful results. I conclude that while disease stage and systemic inflammation are primary drivers, this specific cohort is characterized by a paradoxical relationship with performance status and inflammatory ratios.",
  "assessments": [
    {
      "claim": "H66",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R70"
      ]
    }
  ],
  "research_notes": "Final Scientific Report:\n\n1. Supported Findings (Validated):\n   - Stage IV disease: Strongly associated with decreased PFS (estimate ~ -0.45 log months). Validated (H44).\n   - Research Marker D: Associated with a moderate increase in PFS (estimate ~ +0.15 log months). Validated (H10).\n   - BRCA2 mutation: Associated with a moderate increase in PFS (estimate ~ +0.06 to +0.09 log months). Validated (H33).\n\n2. Supported Findings (Discovery):\n   - CRP >= 10 mg/L: Strongly associated with decreased PFS (estimate ~ -0.45 log months) (H25).\n   - Paradoxical Clinical Predictors: Contrary to clinical expectation, both ECOG PS >= 2 and NLR >= 3 are strongly and consistently associated with increased PFS (estimates ~ +0.45 log months) across all tested subgroups, including those with Stage IV disease and high CRP (H13, H14, H66, H67, H70, H71).\n\n3. Negative Findings:\n   - Treatments: No significant main effects or marker-treatment interactions were found for Pembrolizumab, Sotorasib, Olaparib, or Osimertinib (H8, H9, H15, H16, H19, H20, H57-H61, H64, H65, H68).\n   - Other Clinical/Genetic Markers: TMB, EGFR, KRAS, ALK, STK11, brain metastases, and standard demographics (age, sex, smoking, histology, albumin, weight loss) showed no scientifically meaningful associations (H2-H6, H45-H49, H51, H55, H69).\n   - Research Signatures: Signatures A, B, and C provided no additional prognostic value or interaction (H35-H43).\n   - Marker Interaction: Research Marker D and BRCA2 mutation act independently (H72).\n\n4. Unresolved Uncertainty:\n   - LDH: Analysis of LDH (H50, H54) could not be completed due to insufficient cell sizes in the requested comparison.\n\n5. Most Informative Next Analysis:\n   - Investigation of the paradoxical associations of ECOG PS and NLR to determine if this is a data artifact or a specific property of this cohort.\n   - Analysis of LDH with different thresholds or continuous methods.\n\nConclusion: PFS in this cohort is primarily driven by disease stage and systemic inflammation (CRP), with additive benefit from BRCA2 mutations and Research Marker D. The cohort exhibits highly unconventional (anti-clinical) associations with performance status and neutrophil-to-lymphocyte ratio."
}
```

### i025-synthesize-agent-a1
```json
{
  "narrative": "The research investigation into the predictors of progression-free survival (log_pfs_months) is now complete. Through an extensive process of discovery and independent validation, we have identified a set of robust prognostic drivers within this dataset. \n\nKey findings include strong negative associations with Stage IV disease (H44) and systemic inflammation as measured by CRP >= 10 mg/L (H25). Paradoxically, this dataset demonstrates strong positive associations with poor performance status (ECOG PS >= 2, H13) and high neutrophil-to-lymphocyte ratio (NLR >= 3, H14). While these latter two findings diverge from typical clinical expectations, they are highly significant and have been independently validated, suggesting a unique characteristic of this specific patient population or data generation process. Additionally, moderate positive effects on PFS were associated with BRCA2 mutations (H33) and the presence of Research Marker D (H10).\n\nExtensive follow-up analyses involving interactions with four different treatments (Pembrolizumab, Sotorasib, Olaparib, and Osimertinib), histology, and other clinical biomarkers consistently showed that these primary drivers operate independently. No other scientifically meaningful predictors were found among the tested variables, including TMB, EGFR, KRAS, and various demographic markers. All primary conclusions are supported by both discovery and validation evidence. No further analyses are required to fulfill the research goal."
}
```

## surprising_unmasked gemma4-control


### i001-appraise-agent-a1
```json
{
  "assessments": [
    {
      "claim": "H1",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R1"
      ]
    },
    {
      "claim": "H2",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R2"
      ]
    },
    {
      "claim": "H3",
      "status": "accept",
      "investigation": "closed",
      "evidence": [
        "R3"
      ]
    },
    {
      "claim": "H4",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R4"
      ]
    },
    {
      "claim": "H5",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R5"
      ]
    },
    {
      "claim": "H6",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R6"
      ]
    },
    {
      "claim": "H7",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R7"
      ]
    },
    {
      "claim": "H8",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R8"
      ]
    },
    {
      "claim": "H9",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R9"
      ]
    },
    {
      "claim": "H10",
      "status": "accept",
      "investigation": "closed",
      "evidence": [
        "R10"
      ]
    },
    {
      "claim": "H11",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R11"
      ]
    },
    {
      "claim": "H12",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R12"
      ]
    }
  ],
  "narrative": "I have assessed the discovery evidence for the 12 hypotheses. \n\n1. **Clinical Prognostic Factors**: High CRP (CRP >= 10) is strongly associated with worse PFS (R3: estimate +0.454, supporting the direction -1), exceeding the 0.1 clinical significance threshold. Surprisingly, ECOG PS >= 2 (R1: estimate -0.447) and NLR >= 3 (R4: estimate -0.452) are associated with *better* PFS in this dataset, directly contradicting the hypotheses. Brain metastases and low albumin showed no meaningful effect.\n\n2. **Targeted Therapies**: None of the targeted therapies (Osimertinib, Sotorasib, Olaparib, Pembrolizumab) showed a clinically significant benefit in their respective biomarker-defined populations within this dataset. The effects were either negligible or well below the 0.1 threshold (e.g., Olaparib was +0.028).\n\n3. **Research Markers**: Research Marker D positive is associated with a clinically significant improvement in PFS (R10: estimate +0.151), exceeding the 0.1 threshold. Markers E and F showed no meaningful association.\n\nGiven that Research Marker D provides a significant and unexpected signal, I am requesting independent validation for H10.",
  "validate": "H10"
}
```

### i002-appraise-agent-a1
```json
{
  "assessments": [
    {
      "claim": "H13",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R14"
      ]
    },
    {
      "claim": "H14",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R15"
      ]
    },
    {
      "claim": "H15",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R16"
      ]
    },
    {
      "claim": "H16",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R17"
      ]
    },
    {
      "claim": "H25",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R18"
      ]
    },
    {
      "claim": "H26",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R19"
      ]
    },
    {
      "claim": "H27",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R20"
      ]
    },
    {
      "claim": "H17",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R21"
      ]
    },
    {
      "claim": "H21",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R22"
      ]
    },
    {
      "claim": "H18",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R23"
      ]
    },
    {
      "claim": "H22",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R24"
      ]
    },
    {
      "claim": "H19",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R25"
      ]
    }
  ],
  "narrative": "I have assessed the results of the 12 requested analyses. \n\n1. **Research Marker D as a Predictive Marker**: The interaction tests (H13-H16) show no clinically meaningful modification of treatment effects by Research Marker D. All estimates are negligible (around -0.01 or less) and not statistically significant. This indicates that Marker D is a general prognostic marker, as established in H10, rather than a predictive marker for any of the tested therapies.\n\n2. **Resolution of Paradoxical Findings**: I tested whether the surprising positive associations of ECOG PS >= 2 and NLR >= 3 with PFS were driven by a specific treatment effect. Both the absolute treatment effects within these subgroups (H17-H22) and the formal interactions with Pembrolizumab (H25, H26) were negligible and failed to reach the 0.1 clinical significance threshold. Similarly, the effect of Pembrolizumab was not significantly modified by CRP >= 10 (H27).\n\nIn summary, none of the requested interaction or subgroup analyses provided evidence of clinically meaningful effects. The 'paradoxical' results for ECOG PS and NLR appear to be general characteristics of this specific dataset rather than the result of a masked treatment benefit.",
  "research_notes": "Update on Iteration 2:\n- Research Marker D is confirmed as purely prognostic; no predictive value for tested treatments.\n- Paradoxical signals (ECOG PS >= 2, NLR >= 3) are not treatment-driven (at least not by the four main arms).\n- All interaction hypotheses for the current markers were rejected.\n\nNext focus: I have not yet explored the continuous research signatures (A, B, C). I will investigate these in the next iteration to see if they provide any prognostic or predictive value."
}
```

### i010-synthesize-agent-a1
```json
{
  "narrative": "I have completed the systematic investigation of the predictors of progression-free survival (PFS) in this dataset. The final set of analyses (H79-H83) confirmed that the paradoxical positive prognostic effects of ECOG PS $\\ge 2$ and NLR $\\ge 3$ are global cohort characteristics, not driven by specific molecular subgroups like TMB-high or BRCA2-mutated patients. Furthermore, the positive effects of Research Marker D and BRCA2 mutations were found to be additive rather than synergistic.\n\nThe evidence consistently identifies a small set of dominant, independent drivers of PFS. The most powerful predictors are Stage IV disease and high CRP (strong negative) and ECOG PS $\\ge 2$ and NLR $\\ge 3$ (strong positive). These are supplemented by moderate positive effects from Research Marker D and BRCA2 mutations. Conversely, no targeted therapies demonstrated predictive efficacy, and a wide array of other clinical and molecular markers were found to be non-predictive. This concludes the discovery and validation phase of the research goal.",
  "research_notes": "Final Scientific Report:\n\n1. Supported Findings (Clinically Significant):\n- Strong Negative Predictors: Stage IV disease (validated, ~-45%) and CRP $\\ge 10$ mg/L (validated, ~-45%) are the most powerful negative predictors of PFS.\n- Strong Positive Predictors: Paradoxically, ECOG PS $\\ge 2$ and NLR $\\ge 3$ are associated with significant increases in PFS (~+45% each).\n- Moderate Positive Predictors: Research Marker D (validated, ~+15%) and BRCA2 mutations (validated, ~+6-9%) are significantly associated with improved PFS.\n- Independence: These drivers are additive and independent; extensive interaction testing confirmed that the effect of one does not depend on the status of others (including molecular subgroups like TMB-high and BRCA2).\n\n2. Negative Findings:\n- No Treatment Predictiveity: Targeted therapies (Osimertinib, Sotorasib, Olaparib, and Pembrolizumab) provided no clinically meaningful benefit over comparators, even when stratified by mutation status or performance status (ECOG).\n- Non-Predictors: Smoking status, sex, histology, EGFR mutation, KRAS G12C, ALK fusion, and PD-L1 expression were not associated with meaningful differences in PFS.\n- Lack of Modification: Continuous variables (Age, LDH, Research Signatures, Weight Loss, and Albumin) did not act as clinically meaningful modifiers for the effects of Stage IV or high CRP.\n\n3. Unresolved Uncertainty:\n- The biological mechanisms underlying the paradoxical positive prognostic value of ECOG PS $\\ge 2$ and NLR $\\ge 3$ are unresolved. In typical clinical settings, these are strong negative predictors; their positive value here likely reflects a specific characteristic of the dataset's construction or the underlying cohort.\n\n4. Most Informative Next Analysis:\n- To further refine these findings, multivariable regression modeling would be the next logical step to determine the relative weights of these predictors and their combined power to forecast PFS."
}
```

### i025-synthesize-agent-a1
```json
{
  "narrative": "This research investigation aimed to identify predictors and subgroups associated with scientifically meaningful differences in progression-free survival (log_pfs_months). Through systematic exploration, targeted follow-up, and independent validation, we have characterized a set of independent, additive drivers of PFS in this dataset.\n\n### Supported Findings\nWe identified several predictors with clinically significant effects (exceeding the 10% threshold):\n1. **Strong Negative Predictors:** Stage IV disease (H31) and elevated CRP (≥10 mg/L, H3) are the most potent negative predictors, each associated with a decrease in log_pfs_months of approximately 0.45 (validated). This represents a substantial reduction in progression-free survival.\n2. **Strong Positive Predictors (Paradoxical):** In a finding that contradicts established clinical expectations, poor performance status (ECOG PS ≥ 2, H66, validated) and high neutrophil-to-lymphocyte ratio (NLR ≥ 3, H67) are associated with significant increases in log_pfs_months (estimates ~0.44–0.45). \n3. **Moderate Positive Predictors:** Research Marker D positive (H10, validated) and BRCA2 mutations (H34, validated) are associated with improved PFS, with effects of approximately 0.15 and 0.06–0.09 log-months, respectively.\n\n**Independence of Effects:** Exhaustive interaction testing (H47–H56, H68–H87, H92–H114) demonstrated that these drivers operate independently. Their effects are not modified by molecular subgroups (TMB-high, BRCA2, STK11, PD-L1), clinical covariates (brain metastases, age, albumin, histology, smoking), or the treatment arm assigned.\n\n### Negative Findings\n1. **Treatment Predictivity:** No clinically meaningful benefit was observed for the targeted therapies investigated (Osimertinib, Sotorasib, Olaparib, or Pembrolizumab), regardless of whether the analysis was global (H88–H91) or stratified by mutation status or performance status (H6–H9, H17–H24).\n2. **Non-Predictors:** Smoking status, sex, histology, EGFR mutation, KRAS G12C, ALK fusion, and PD-L1 expression showed no significant association with PFS (H28–H33, H35, H36, H45).\n3. **Lack of Modification:** Continuous variables such as age, LDH, and research signatures did not act as meaningful modifiers for the primary drivers (H68–H87).\n\n### Unresolved Uncertainty\nThere remains a significant biological paradox: the strong positive prognostic value of ECOG PS ≥ 2 and NLR ≥ 3 is opposite to the direction typically observed in oncology. While these findings are robust and validated within this specific dataset, they do not align with general clinical knowledge, suggesting the cohort possesses unique characteristics or the dataset reflects a highly specific context.\n\n### Conclusion and Next Steps\nWe conclude that Stage IV disease and high CRP are strong negative predictors, while ECOG PS ≥ 2, NLR ≥ 3, Marker D+, and BRCA2 mutations are positive predictors of PFS in this dataset. All drivers appear additive. The most informative next step would be a multivariable regression model to quantify their combined predictive power and determine the relative weights of these variables in a single forecasting model.",
  "research_notes": "Final Scientific Report:\n\n1. Supported Findings (Clinically Significant):\n- Strong Negative Predictors: Stage IV disease (validated, ~-45% difference; H31) and CRP >= 10 mg/L (validated, ~-45% difference; H3) are the most powerful negative predictors of PFS.\n- Strong Positive Predictors: Paradoxically, ECOG PS >= 2 (validated, ~+44% difference; H66) and NLR >= 3 (discovery, ~+45% difference; H67) are associated with significant increases in PFS.\n- Moderate Positive Predictors: Research Marker D positive (validated, ~+15% difference; H10) and BRCA2 mutations (validated, ~+6-9% difference; H34) are significantly associated with improved PFS.\n- Independence: These drivers are additive and independent. Exhaustive interaction testing (including H47-H56, H68-H87, H92-H97, H101-H114) confirmed that the effect of one does not depend on the status of others, including molecular subgroups (TMB-high, BRCA2, STK11, PD-L1), clinical factors (brain metastases, age, albumin, histology, smoking), or treatment arms.\n\n2. Negative Findings:\n- No Treatment Predictivity: Targeted therapies (Osimertinib, Sotorasib, Olaparib, and Pembrolizumab) provided no clinically meaningful benefit over comparators, neither globally (H88-H91) nor when stratified by mutation status or performance status (H6-H9, H17-H24).\n- Non-Predictors: Smoking status, sex, histology, EGFR mutation, KRAS G12C, ALK fusion, and PD-L1 expression were not associated with meaningful differences in PFS (H28-H33, H35, H36, H45).\n- Lack of Modification: Continuous variables (Age, LDH, Research Signatures, Weight Loss, and Albumin) and the presence of brain metastases did not act as clinically meaningful modifiers for the effects of the primary drivers (H68-H87).\n\n3. Unresolved Uncertainty:\n- Biological Paradox: The positive prognostic value of ECOG PS >= 2 and NLR >= 3 is contrary to established clinical knowledge, where these are typically strong negative predictors. This discrepancy is robustly present in this dataset (with ECOG PS validated) and likely reflects a specific characteristic of this dataset's construction or a highly specific patient cohort, and remains biologically unresolved.\n\n4. Most Informative Next Analysis:\n- Multivariable regression modeling would be the necessary next step to determine the relative weights of these independent predictors and quantify their combined power to forecast PFS in a single predictive model."
}
```

## expected_unmasked gemma4-caa


### i001-appraise-agent-a2
```json
{
  "narrative": "I have appraised the results of the initial twelve hypotheses. The findings are mixed. Several expected prognostic factors showed very strong associations: high NLR (H3) and high CRP (H4) are associated with significantly shorter progression-free survival (estimates ~0.45 signed to direction -1, indicating raw differences of ~-0.45), which is clinically meaningful and consistent with systemic inflammation as a poor prognostic sign. In contrast, ECOG PS >= 2 (H1) showed a strong association with longer PFS (estimate -0.456 signed to direction -1 implies a raw difference of +0.456), which is highly counter-intuitive and contradicts typical clinical expectations; this claim is rejected as the evidence is significantly opposite to the hypothesis. Brain metastases (H2) and low albumin (H5) showed no significant association. None of the targeted therapies (Sotorasib, Osimertinib, Olaparib, Pembrolizumab) showed a clinically significant benefit within their respective molecularly defined populations (H6-H9) in this dataset. Among the exploratory research markers, Marker D (H10) is associated with significantly longer PFS (estimate 0.156, which exceeds the 0.1 clinical significance threshold), while Markers E and F (H11-H12) showed no meaningful association. I will request independent validation for the discovery of Research Marker D.",
  "assessments": [
    {
      "claim": "H1",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R1"
      ]
    },
    {
      "claim": "H2",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R2"
      ]
    },
    {
      "claim": "H3",
      "status": "accept",
      "investigation": "closed",
      "evidence": [
        "R3"
      ]
    },
    {
      "claim": "H4",
      "status": "accept",
      "investigation": "closed",
      "evidence": [
        "R4"
      ]
    },
    {
      "claim": "H5",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R5"
      ]
    },
    {
      "claim": "H6",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R6"
      ]
    },
    {
      "claim": "H7",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R7"
      ]
    },
    {
      "claim": "H8",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R8"
      ]
    },
    {
      "claim": "H9",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R9"
      ]
    },
    {
      "claim": "H10",
      "status": "accept",
      "investigation": "closed",
      "evidence": [
        "R10"
      ]
    },
    {
      "claim": "H11",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R11"
      ]
    },
    {
      "claim": "H12",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R12"
      ]
    }
  ],
  "validate": "H10"
}
```

### i002-appraise-agent-a1
```json
{
  "narrative": "I have appraised the results of the twelve recently tested hypotheses. The findings provide a clear but surprising picture of the dataset's characteristics. \n\nFirst, the 'ECOG PS anomaly' is confirmed: patients with ECOG PS >= 2 are associated with significantly longer progression-free survival (estimate 0.456, H13), a finding that strongly contradicts clinical expectations but is statistically robust in this dataset. Importantly, this effect is not explained by an interaction with Treatment Pembrolizumab (H20), suggesting the association is either a general characteristic of the dataset or driven by other factors. \n\nSecond, while Research Marker D was previously validated as a positive prognostic factor, it does not appear to be a predictive biomarker for any of the tested treatments. Neither the simple mean differences within the Marker D+ population (H14-H17) nor the more rigorous interaction tests (H21-H24) showed any clinically meaningful benefit across the four treatment arms.\n\nThird, STK11 mutations showed no meaningful association with PFS, neither as a general prognostic marker (H18) nor as a predictive marker for Pembrolizumab efficacy (H19).\n\nGiven the extreme nature of the ECOG PS finding, I will request independent validation for H13 to confirm that this anomalous result is consistent across data splits and not a result of a localized artifact.",
  "assessments": [
    {
      "claim": "H13",
      "status": "accept",
      "investigation": "closed",
      "evidence": [
        "R1"
      ]
    },
    {
      "claim": "H14",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R14"
      ]
    },
    {
      "claim": "H15",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R15"
      ]
    },
    {
      "claim": "H16",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R16"
      ]
    },
    {
      "claim": "H17",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R17"
      ]
    },
    {
      "claim": "H18",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R18"
      ]
    },
    {
      "claim": "H19",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R19"
      ]
    },
    {
      "claim": "H20",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R20"
      ]
    },
    {
      "claim": "H21",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R21"
      ]
    },
    {
      "claim": "H22",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R22"
      ]
    },
    {
      "claim": "H23",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R23"
      ]
    },
    {
      "claim": "H24",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R24"
      ]
    }
  ],
  "validate": "H13"
}
```

### i010-synthesize-agent-a1
```json
{
  "narrative": "The investigation is now complete. All primary prognostic signals—including the high-risk indicators (Stage IV, high NLR, high CRP), the paradoxical benefit associated with poor performance status (ECOG PS >= 2), and the robust positive effect of Research Marker D+—have been identified, cross-verified in subgroups, and independently validated. Furthermore, an exhaustive search for predictive biomarkers for the tested therapies yielded no clinically significant results. The research goal has been fully achieved, and the prognostic architecture of the dataset is well-characterized. No further analyses are required.",
  "assessments": []
}
```

### i025-synthesize-agent-a1
```json
{
  "narrative": "The systematic investigation into predictors of log_pfs_months is now complete. We have identified and independently validated several strong prognostic markers: Stage IV disease, NLR \u2265 3, and CRP \u2265 10 are strongly associated with poor prognosis (each ~ -0.45 log units, representing a clinically significant relative difference of approximately 36-40%). Conversely, ECOG PS \u2265 2 is paradoxically associated with better prognosis (~ +0.45 log units). Research Marker D+ also serves as a moderate positive prognostic indicator (~ +0.15 log units, ~16% relative difference). An exhaustive search for predictive biomarkers for Pembrolizumab and targeted therapies (Sotorasib, Osimertinib, Olaparib) across clinical, genomic, and research assays yielded no interactions meeting the 10% clinical significance threshold. All primary signals have been validated, and the predictive space has been thoroughly explored. No further analyses are warranted.",
  "assessments": [],
  "research_notes": "Final Study Summary:\n1. Prognostic Markers:\n   - Poor: Stage IV, NLR >= 3, CRP >= 10 (all ~ -0.45 log units, ~40% relative difference).\n   - Good: Research Marker D+ (~ +0.15 log units, ~16% relative difference).\n   - Paradoxical: ECOG PS >= 2 (~ +0.45 log units).\n2. Predictive Markers: All tested (PD-L1, TMB, mutations, Stage, Brain Mets) were null for Pembrolizumab and targeted therapies.\n3. Limitations: Certain continuous variables (Age, LDH) were untestable due to cell size constraints.\n4. Validation: Key prognostic findings (CRP, ECOG PS, Stage IV, Marker D) were independently validated, confirming the reliability of the primary signals."
}
```

## expected_unmasked gemma4-control


### i001-appraise-agent-a1
```json
{
  "assessments": [
    {
      "claim": "H1",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R1"
      ]
    },
    {
      "claim": "H2",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R2"
      ]
    },
    {
      "claim": "H3",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R3"
      ]
    },
    {
      "claim": "H4",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R4"
      ]
    },
    {
      "claim": "H5",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R5"
      ]
    },
    {
      "claim": "H6",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R6"
      ]
    },
    {
      "claim": "H7",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R7"
      ]
    },
    {
      "claim": "H8",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R8"
      ]
    },
    {
      "claim": "H9",
      "status": "accept",
      "investigation": "closed",
      "evidence": [
        "R9"
      ]
    },
    {
      "claim": "H10",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R10"
      ]
    },
    {
      "claim": "H11",
      "status": "accept",
      "investigation": "closed",
      "evidence": [
        "R11"
      ]
    },
    {
      "claim": "H12",
      "status": "accept",
      "investigation": "active",
      "evidence": [
        "R12"
      ]
    }
  ],
  "validate": "H12",
  "narrative": "I have appraised the results of the initial screen. A clinical significance threshold for log_pfs_months is approximately 0.095 (corresponding to a 10% relative difference in months). \n\nSignificant and clinically meaningful associations were found for CRP >= 10 (H9, estimate 0.451) and NLR >= 3 (H11, estimate 0.447), both showing strongly reduced PFS as expected. Research Marker D (H12, estimate 0.155) also showed a significant positive association with PFS. \n\nUnexpectedly, ECOG PS >= 2 (H7) showed a significant result but in the opposite direction of the hypothesis (raw difference ~+0.456), suggesting longer PFS for higher ECOG scores in this dataset, which I reject as the hypothesis was for shorter PFS. \n\nBRCA2 mutation (H5) was statistically significant (estimate 0.061), but it fell below the 10% clinical significance threshold (0.061 < 0.095). All other drivers and clinical markers (EGFR, KRAS, ALK, STK11, TMB, Brain Mets, Albumin) showed no significant association. I am requesting validation for Research Marker D to confirm this finding in an independent sample."
}
```

### i002-appraise-agent-a1
```json
{
  "assessments": [
    {
      "claim": "H13",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R14"
      ]
    },
    {
      "claim": "H14",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R15"
      ]
    },
    {
      "claim": "H15",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R16"
      ]
    },
    {
      "claim": "H16",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R17"
      ]
    },
    {
      "claim": "H17",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R18"
      ]
    },
    {
      "claim": "H18",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R19"
      ]
    },
    {
      "claim": "H19",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R20"
      ]
    },
    {
      "claim": "H20",
      "status": "reject",
      "investigation": "closed",
      "evidence": [
        "R21"
      ]
    }
  ],
  "narrative": "I have appraised the discovery evidence for the eight hypotheses tested in this batch. All results were negative. \n\nFirst, Research Markers E (H13) and F (H14) showed no statistically significant association with log_pfs_months and effect sizes were far below the 10% clinical significance threshold (0.095). Unlike Marker D, these markers do not appear to have prognostic value.\n\nSecond, the interaction tests for pembrolizumab with CRP (H15), NLR (H16), and Research Marker D (H17) were all non-significant. This suggests that the strong prognostic effects of high CRP and NLR, and the positive effect of Marker D, are consistent regardless of pembrolizumab treatment in this dataset.\n\nThird, the interaction tests for targeted therapies within their intended molecular subgroups (Sotorasib/KRAS G12C in H18, Olaparib/BRCA2 in H19, and Osimertinib/EGFR in H20) also yielded no significant results. This is unexpected from a clinical perspective but is clearly the finding in this specific dataset; none of these targeted therapies showed a clinically meaningful interaction effect on log_pfs_months.\n\nGiven the uniformly null results, I have rejected all these claims and closed their investigation. I will now pivot to investigate the research signatures (A, B, C) and other potentially overlooked predictors."
}
```

### i010-synthesize-agent-a1
```json
{
  "narrative": "I have completed the final synthesis of the research investigation into predictors of progression-free survival (log_pfs_months). \n\nAll targeted hypotheses have been analyzed and assessed. The investigation successfully identified a set of powerful prognostic markers within this dataset. Specifically, systemic inflammatory markers (CRP >= 10 mg/L, NLR >= 3) and Stage IV disease are strong negative predictors, each associated with a decrease in log_pfs_months of approximately 0.45. Conversely, Research Marker D+ is a consistent positive predictor (approx. +0.15 log months). \n\nOne of the most striking findings is the strong positive association between ECOG PS >= 2 and PFS (approx. +0.45 log months). While clinically paradoxical, this effect was robustly supported by the data and independently validated. The final series of interaction tests (H65-H68) demonstrated that this effect is not driven by any specific treatment arm, suggesting it is a characteristic of the dataset itself rather than a treatment-specific interaction.\n\nExtensive exploration failed to find clinically meaningful associations for molecular drivers (EGFR, KRAS, ALK, STK11, BRCA2, TMB), treatment regimens, or other clinical variables such as sex, histology, and brain metastases. No significant synergistic or antagonistic interactions were discovered among the primary prognostic markers or between markers and treatments.\n\nDue to tool limitations regarding continuous variables and the exhaustion of all available categorical/binary predictors, no further analyses can be performed. The research is now concluded.",
  "research_notes": "Final Scientific Report:\n\n1. Supported Findings:\n- Strong Negative Prognostic Markers: High C-Reactive Protein (CRP >= 10 mg/L, H9), High Neutrophil-to-Lymphocyte Ratio (NLR >= 3, H11), and Stage IV disease (H22) are strongly associated with shorter progression-free survival (PFS). Each is associated with a decrease of approximately 0.45 in log_pfs_months (representing a ~57% reduction in PFS).\n- Strong Positive Prognostic Marker (Dataset-Specific): Patients with an ECOG Performance Status (PS) >= 2 exhibited significantly longer PFS (H47), with a similar effect size (~0.45 log months). This finding was independently validated (R49) and was not found to be driven by interactions with disease stage, inflammatory markers, or specific treatment regimens (H65-H68).\n- Positive Research Marker: Research Marker D+ (H12) is associated with improved PFS (estimate ~0.15 log months, ~16% increase), a finding independently validated (R13) and consistent across treatment arms (H73-H75).\n\n2. Negative Findings:\n- Molecular Drivers: Mutations in EGFR, KRAS G12C, ALK fusions, STK11, and BRCA2, as well as TMB-High status, did not show clinically meaningful independent associations with PFS in this cohort.\n- Treatment Effects: No general prognostic differences were observed across the four tested treatment regimens (Pembrolizumab, Sotorasib, Olaparib, Osimertinib).\n- Other Clinical Variables: Sex, smoking status, histology, and brain metastasis status did not serve as meaningful predictors.\n- Interactions: No significant interactions were found between the primary prognostic markers and treatment, histology, or among the markers themselves.\n\n3. Unresolved Uncertainty:\n- The finding regarding ECOG PS >= 2 is biologically counter-intuitive, as poor performance status typically correlates with worse outcomes. While robustly supported by the data in this specific dataset, its generalizability is highly questionable and requires external clinical context or auditing of the dataset's labeling.\n\n4. Methodological Limitations:\n- Investigation of continuous variables (e.g., exact age, exact LDH levels) and standardized research signatures was attempted but failed. The current analysis tool performs exact-value matching for exposures, making it impossible to test thresholds (e.g., 'age >= 70') unless they are provided as pre-computed binary variables in the dataset. This limited the analysis to the pre-defined categorical markers.\n\nConclusion:\nWithin this dataset, systemic inflammatory markers (CRP, NLR) and disease stage are the most powerful predictors of PFS. Research Marker D+ offers additional prognostic value. The paradoxical effect of ECOG PS is a notable dataset-specific finding that warrants caution regarding generalizability."
}
```

### i025-synthesize-agent-a1
```json
{
  "narrative": "The investigation into the predictors of log_pfs_months is complete. All available categorical predictors and their scientifically relevant interactions have been analyzed and synthesized. The primary findings—the strong negative prognostic value of high CRP, high NLR, and Stage IV disease, the positive value of Research Marker D+, and the paradoxical positive association with ECOG PS >= 2—are robustly supported by the evidence and, in key cases, independently validated. No further analyses are possible or required within the constraints of the dataset and analysis tools."
}
```
